← All trials
NCT05162482
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Dec 17, 2021
- Last posted
- Dec 17, 2021
- Enrollment
- 1680
- Arms / groups
- 9 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Aga Khan UniversityLead sponsor
- University of OxfordStudy director
- University of OxfordCollaborator
- International Vaccine InstituteCollaborator
- Coalition for Epidemic Preparedness InnovationsCollaborator
- Aga Khan UniversityReponsible party - principal investigator
- Harvard UniversityCollaborator
- Aga Khan UniversityOverall official - principal investigator
- Aga Khan UniversityStudy director
- Chughtai LabCollaborator
- Government of PakistanStudy director
- Government of PakistanCollaborator
- International Vaccine InstituteStudy director
- Harvard UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.